🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

150 results for “chemotherapy” Clear

  1. Herombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

  2. Hypofractionated radiation/chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  3. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy

    phase 2 small molecule active

    1 trial

  4. IMFINZI 50 mg/mL concentrate for solution for infusion., FLUOROURACIL, FOLINIC ACID, OXALIPLATIN

    Ningbo Cancer Hospital

    Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy

    phase 2 small molecule active

    1 trial

  5. Immunotherapy combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  6. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  7. Ivonescimab Combined With Chemotherapy

    The First People's Hospital of Lianyungang

    Pretreated Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  8. LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

    The George Institute

    Colon cancer

    phase 2 other active

    1 trial

  9. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Verona Pharma Ireland Limited

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial

  10. MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX

    Novartis Pharmaceuticals

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  11. Neoadjuvant Chemotherapy

    Xiangya Hospital of Central South University

    High-Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  12. Neoadjuvant Chemotherapy (NACT)

    The First People's Hospital of Lianyungang

    HR+/HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  13. Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  14. Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. PACLITAXEL, MYCOPHENOLATE MOFETIL, volrustomig, INFLIXIMAB, FLUOROURACIL, CISPLATIN

    AstraZeneca AB

    Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).

    phase 2 small molecule active

    1 trial

  16. PD-1 Inhibitor plus Chemotherapy

    Sichuan University

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  17. Palmidrol

    United Therapeutics Europe Ltd

    Chemotherapy-Induced Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  18. Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

    The George Institute

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  19. Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma

    The George Institute

    Malignant Peritoneal Mesothelioma

    phase 2 other active

    1 trial

  20. Pre-operative chemotherapy

    Nanjing Zenshine Pharmaceuticals

    Gastric Cancers

    phase 2 small molecule active

    1 trial

  21. Pre-operative chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors

    The George Institute

    Pancreatic well differentiated neuroendocrine tumors (NET)

    phase 2 other active

    1 trial

  23. Revlimid 5 mg hard capsules, DEXAMETHASONE, DEXAMETHASONE , DARZALEX 1800 mg solution for injection, BORTEZOMIB , Revlimid 10 mg hard capsules, BORTEZOMIB, DEXAMETHASONE

    Pari Pharma GmbH

    PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION

    phase 2 small molecule active

    1 trial

  24. Romiplostim N01

    Hospital Authority, Hong Kong

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources